Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.54 |
| ▸ | SKP1 | P63208 | 2/20 | 0.54 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | ACACB | O00763 | 9/20 | 0.45 |
| ▸ | ACACA | Q13085 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8217776 | 0.90 | DRD2 (0.51) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL7093978 | 0.81 | CKS1B (0.52) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL12068751 | 0.79 | CKS1B (0.51) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL8224861 | 0.79 | ADAM17 (0.44) | DRD2KDM4EPKM | |
| SCHEMBL3436642 | 0.78 | CKS1B (0.59) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL9984934 | 0.78 | CKS1B (0.56) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL3199650 | 0.77 | CKS1B (0.58) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL8214672 | 0.77 | BPTF (0.42) | DRD2KDM4EPKM | |
| SCHEMBL12068465 | 0.76 | CKS1B (0.48) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL8222029 | 0.76 | CKS1B (0.53) | CKS1BSKP1SKP2DRD2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | CKS1B 4036/4885SKP1 1701/4885SKP2 4198/4885 |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | CKS1B 2868/4885SKP1 3500/4885SKP2 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.